Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Boris Tchounga is active.

Publication


Featured researches published by Boris Tchounga.


Journal of the International AIDS Society | 2014

Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of The West African Database to evaluate AIDS collaboration

Boris Tchounga; André Inwoley; Patrick A. Coffie; Daouda Minta; Eugène Messou; Guillaume Bado; Albert Minga; Denise Hawerlander; Coumba Toure Kane; Serge Eholié; François Dabis; Didier K. Ekouevi

West Africa is characterized by the circulation of HIV‐1 and HIV‐2. The laboratory diagnosis of these two infections as well as the choice of a first‐line antiretroviral therapy (ART) is challenging, considering the limited access to second‐line regimens. This study aimed at confirming the classification of HIV‐2 and HIV‐1&2 dually reactive patients followed up in the HIV‐2 cohort of the West African Database to evaluate AIDS collaboration.


BMC Health Services Research | 2014

Cervical cancer prevention in reproductive health services: knowledge, attitudes and practices of midwives in Côte d’Ivoire, West Africa

Boris Tchounga; Antoine Jaquet; Patrick A. Coffie; Apollinaire Horo; Catherine Sauvaget; Innocent Adoubi; Privat Guie; François Dabis; Annie J. Sasco; Didier K. Ekouevi

BackgroundCervical cancer is the most common cancer among women and the leading cause of cancer deaths in women in Côte d’Ivoire. Low resource countries can now prevent this cancer by using HPV vaccine and effective and affordable screening tests. However the implementation of these prevention strategies needs well-trained human resources. Part of the solution could come from midwives by integrating cervical cancer prevention into reproductive health services. The aim of this survey was to assess knowledge, attitudes and practices of midwives towards cervical cancer prevention in Abidjan, Côte d’Ivoire, and to find out factors associated with appropriate knowledge.MethodsA cross-sectional survey was conducted among midwives in the urban district of Abidjan, using a self-administered questionnaire. Knowledge was assessed by two scores. Factors associated with appropriate knowledge were determined using a logistic regression analysis. Attitudes and practices were described and compare using the Chi2 test.ResultsA total of 592 midwives were enrolled, including 24.5% of final-year students. 55.7% of midwives had appropriate knowledge on cervical cancer, and 42.4% of them had appropriate knowledge on cervical cancer prevention strategies. Conferences, courses taken at school of midwifery and special training sessions on cervical cancer (OR = 4.9, 95% CI [1.9 to 12.6], p <0.01) were associated with good knowledge on the management of this disease. Among these midwives, 18.4% had already benefited from a screening test for themselves, 37.7% had already advised screening to patients and 8.4% were able to perform a visual inspection. 50.3% of midwives knew HPV vaccine as a preventive method; among them 70.8% usually recommended it to young girls.ConclusionDespite sufficient knowledge about cervical cancer prevention, attitudes and practices of midwives should be improved by organizing capacity building activities. This would ensure the success of integration of cervical cancer prevention into reproductive health services in countries like Côte d’Ivoire.


PLOS ONE | 2015

Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration

Didier K. Ekouevi; Véronique Avettand-Fenoel; Boris Tchounga; Patrick A. Coffie; Adrien Sawadogo; Daouda Minta; Albert Minga; Serge Eholié; Jean-Christophe Plantier; Florence Damond; François Dabis; Christine Rouzioux

Background Plasma HIV-1 RNA monitoring is one of the standard tests for the management of HIV-1 infection. While HIV-1 RNA can be quantified using several commercial tests, no test has been commercialized for HIV-2 RNA quantification. We studied the relationship between plasma HIV-2 viral load (VL) and CD4 count in West African patients who were either receiving antiretroviral therapy (ART) or treatment-naïve. Method A cross sectional survey was conducted among HIV-2-infected individuals followed in three countries in West Africa from March to December 2012. All HIV-2 infected-patients who attended one of the participating clinics were proposed a plasma HIV-2 viral load measurement. HIV-2 RNA was quantified using the new ultrasensitive in-house real-time PCR assay with a detection threshold of 10 copies/ mL (cps/mL). Results A total of 351 HIV-2-infected individuals participated in this study, of whom 131 (37.3%) were treatment naïve and 220 (62.7%) had initiated ART. Among treatment-naïve patients, 60 (46.5%) had undetectable plasma HIV-2 viral load (<10 cps/mL), it was detectable between 10-100 cps/mL in 35.8%, between 100-1000 cps/mL in 11.7% and >1000 cps/mL in 6.0% of the patients. Most of the treatment-naïve patients (70.2%) had CD4-T cell count ≥500 cells/mm3 and 43 (46.7%) of these patients had a detectable VL (≥10 cps/mL). Among the 220 patients receiving ART, the median CD4-T cell count rose from 231 to 393 cells/mm3 (IQR [259-561]) after a median follow-up duration of 38 months and 145 (66.0%) patients had CD4-T cell count ≤ 500 cells/mm3 with a median viral load of 10 cps/mL (IQR [10-33]). Seventy five (34.0%) patients had CD4-T cell count ≥ 500 cells/mm3, among them 14 (18.7%) had a VL between 10-100 cps/mL and 2 (2.6%) had VL >100 cps/mL. Conclusion This study suggests that the combination of CD4-T cell count and ultrasensitive HIV-2 viral load quantification with a threshold of 10 cps/mL, could improve ART initiation among treatment naïve HIV-2-infected patients and the monitoring of ART response among patients receiving treatment.


Journal of the International AIDS Society | 2016

Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort

Eric Balestre; Didier K. Ekouevi; Boris Tchounga; Serge P. Eholie; Eugène Messou; Adrien Sawadogo; Rodolphe Thiébaut; Margaret T May; Jonathan A C Sterne; François Dabis

Response to antiretroviral therapy (ART) among individuals infected with HIV‐2 is poorly described. We compared the immunological response among patients treated with three nucleoside reverse‐transcriptase inhibitors (NRTIs) to boosted protease inhibitor (PI) and unboosted PI‐based regimens in West Africa.


Current Opinion in Hiv and Aids | 2016

Mortality and survival patterns of people living with HIV-2.

Boris Tchounga; Didier K. Ekouevi; Eric Balestre; François Dabis

Purpose of reviewPeople living with HIV-2 infected usually initiate antiretroviral therapy (ART) at an advanced period in the course of their infection after a long asymptomatic period characterized by high CD4 cell count and thus at a relatively advanced age. In the new international context of early and universal ART initiation, the aim was to review survival patterns among HIV-2 infected patients, either on ART or not. Recent findingsVery few reports were published on mortality in people living with HIV-2 during the last 5 years. People living with HIV-2 experience high mortality rates although lower than people living with HIV-1 before ART initiation. They seem to survive longer regardless of the conditions of ART use. Mortality is associated with late presentation, male sex, CD4 cell count less than 500 cell/&mgr;l, high plasma viral load, hemoglobin rate less than 8 g/dl and body mass index less than 18 kg/m2. SummaryPeople living with HIV-2 initiate ART later than HIV-1 and HIV duals, resulting in higher disease progression and mortality rate. The clinical management of HIV-2 infected patients should now include early diagnosis and treatment initiation as per international guidelines. Further research needs to explore the ‘what to start’ question and document specific causes of death in people living with HIV-2 and enrolled in care in Africa.


The Pan African medical journal | 2016

Condom use and associated factors among men who have sex with men in Togo, West Africa.

Tchaa Abalo Bakai; Didier K. Ekouevi; Boris Tchounga; Eric Balestre; Kossivi Agbélénko Afanvi; Kariyiare Benjamin Goilibe; Yao Kassankogno; Vincent Palokinam Pitche

Introduction In 2011, the prevalence of HIV among men who have sex with men (MSM) in Togo was estimated at 19.6% compared to 3.4% in the general population. This study aimed to describe condom use and associated factors among MSM in Togo. Methods In 2011, a cross-sectional survey was conducted using the snowball sampling method among MSM in Togo. This study enrolled MSM aged 18 years and above who reported having sexual contact with other men within the last 30 days. A standardized survey form was used for data collection, and multivariate analyses were performed. Results A total of 724 MSM were included in this study. The median age was 25 years [22-28], 90.3% had at least a secondary school level. The sexual practices during the last sexual encounter with another man included: insertive anal sex (62.2%), receptive anal sex (56.6%), oral sex (33.8%) and oral-anal sex (8.6%). A condom was used during the last insertive and receptive anal encounters in 78.4% and 81.2% of the time, respectively. In multivariate analysis, condom use was positively associated with previous participation in HIV/STD prevention activities (aOR=1.72; 95% CI=[1.09-2.71]), with the consideration of the last sexual partner as a casual one (aOR=1.87; 95% CI=[1.24-2.82]) and with having at least a secondary school level (aOR=2.40; 95% CI=[1.22-4.69]). Conclusion One out of five MSM did not use a condom during the last anal encounter with another man. HIV prevention programs in Africa should develop specific interventions targeting MSM to reduce the incidence of HIV in this hidden population.


AIDS | 2016

Effect of sex and age on outcomes among hiv-2 infected patients starting antiretroviral therapy in west africa

Boris Tchounga; Bo Langhoff Hønge; Serge Eholié; Patrick A. Coffie; Sanne Jespersen; Christian Wejse; François Dabis; Gottlieb S. Geoffrey; Didier K. Ekouevi

Objectives:HIV-2-infected individuals usually initiate antiretroviral therapy (ART) at an advanced age compared with HIV-1 patients, with a potential impact on treatment outcomes. This study aimed to investigate the effect of sex and age on mortality and loss to follow-up (LTFU) among HIV-2-infected individuals initiating ART. Methods:Analyses were conducted using the database of the International Epidemiological Databases to Evaluate AIDSs collaboration in West Africa. LTFU was considered if the interval between the last visit and the closing date for this analysis was more than 180 days. Probability of death and LTFU were estimated with Kaplan–Meier methods. A Cox regression model was used to identify factors associated with death and LTFU over the first 24 months on ART. Results:A total of 1825 HIV-2-infected individuals, including 60% women were considered for this analysis. The median age, baseline CD4+ cell count, and follow-up duration were 45 years [interquartile range (IQR; 38–52)], 185 cells/&mgr;l [IQR (95–297)], and 28.8 months [IQR (9.8–58.9)], respectively. Over the first 24 months, the mortality rate was 5.2/100 person-years of observation [95% confidence interval (CI; 4.4–6.1)] and 469 (25.7%) were LTFU. Male sex [hazard ratio (HR) = 1.9; 95% CI (1.4; 2.8)], baseline CD4+ cell count less than 100 cell/&mgr;l [HR = 4.4 95% CI (1.7; 11.1); ref at least 350 cell/&mgr;l], haemoglobin 7.5–10 g/dl [HR = 2.4 95% CI (1.3; 4.4); ref at least 12 g/dl], and BMI less than 18 kg/m2 [HR = 2.1 95% CI (1.3; 3.4); ref = 18–25 kg/m2] were associated with higher mortality over the first 24 months. Similar associations were found for LTFU. Conclusion:Mortality and LTFU are high among ART-receiving HIV-2-infected individuals and higher in men than in women. There is a critical need to further determine the causes of poor retention and implement sex-specific solutions that improve outcomes in HIV-2 ART programmes.


Obstetrics and Gynecology International | 2015

Cervical Cancer Screening Program by Visual Inspection: Acceptability and Feasibility in Health Insurance Companies

Apollinaire Horo; Judith Didi-Kouko Coulibaly; Abdoul Koffi; Boris Tchounga; K. Seni; Kacou Edele Aka; M. Kone

Objective. To assess willingness to participate and diagnostic accuracy of visual inspection for early detection of cervical neoplasia among women in a health insurance company. Patients and Method. Cervical cancer screening was systematically proposed to 800 women after consecutive information and awareness sessions. The screening method was visual inspection with acetic acid (VIA) or Lugols iodine (VILI). Results. Among the 800 identified women, 640 (82%) have accepted the screening, their mean age was 39 years, and 12.0% of them were involved in a polygamist couple. 28.2% of women had prior cervical screening. VIA has been detected positive in 5.9% of women versus 8.6% for VILI. The sensitivity was 72.9% and specificity was 95.2% for VIA versus 71.2% and 97.3% for VILI respectively. The histological examination highlighted a nonspecific chronic cervicitis in 4.6%, CIN1 lesions in 5.91%, and CIN2/3 in 1.2% of the cases. Conclusion. Cervical cancer screening by visual inspection showed appropriate diagnostic accuracy when used to detect early cervical lesions. It is a simple and easy to perform method that could be introduced progressively in the health insurance policy while waiting for a national screening program.


Journal of Public Health in Africa | 2018

Prevalence of hepatitis C among HIV-1, HIV-2 and dually reactive patients: A multi-country cross-sectional survey in West Africa

Didier K. Ekouevi; Patrick A. Coffie; Boris Tchounga; Armel Poda; Antoine Jaquet; François Dabis; Serge Eholié

Little is known on the impact of HIV-2 infection on HCV viral replication. The aim of the study was to compare HCV prevalence and viral replication based on HIV types in West Africa. A cross-sectional survey was conducted within the IeDEA HIV-2 West Africa cohort from March to December 2012. All HIVinfected adult patients who attended participating HIV clinics during the study period were included. Blood samples were collected and re-tested for HIV type discrimination, HCV serology and viral load. A total of 767 patients were enrolled: 186 HIV-1, 431 HIV-2 and 150 HIV-1&2 dually reactive. At time of sampling, 531 (69.2%) were on ART and median CD4+ cell count was 472/mm3. Thirty (3.9%, 95% CI 2.7-5.5) patients were anti-HCV positive (4.3% in HIV-1, 4.0% in HIV-1&2 dually reactive and 3.7% in HIV-2; p=0.91). Detectable HCV RNA was identified in 21 (70.0%) patients (100% in HIV-1 and HIV- 1&2 dually reactive vs. 43.8% in HIV-2; p=0.003). Systematic screening should be promoted and performed in this population, since HCV is now potentially curable in sub- Saharan Africa.


BMC Infectious Diseases | 2014

Antiretroviral therapy response among HIV-2 infected patients: a systematic review

Didier K. Ekouevi; Boris Tchounga; Patrick A. Coffie; Joseph Tegbe; Alexandra M. Anderson; Geoffrey S. Gottlieb; Marco Vitoria; F Dabis; Serge P. Eholie

Collaboration


Dive into the Boris Tchounga's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Didier K. Ekouevi

French Institute of Health and Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Catherine Sauvaget

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

F Dabis

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge